Intravitreal Lower- Dose (20 mu g) Melphalan for Persistent or Recurrent Retinoblastoma Vitreous Seeds

Abstract

BACKGROUND AND OBJECTIVE: The major cause of failure in the management of retinoblastoma is the persistence/recurrence of vitreous seeds (VS). This study reports the efficacy and complications of standard lower-dose (20 mu g) intravitreal melphalan for VS.